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studies has supported that psychiatric disorders in adults typically
onset in childhood and adolescence which not uncommonly debut as
non-speciﬁc symptoms and syndromes (i.e. heterotypy) (Kim-Cohen
et al., 2003; Duffy, 2015). Studying multiple indicators of illness risk
and development longitudinally within high-risk subjects is increasing-
ly recognized as important in order to differentiate vulnerability from
burden of illness effects and to identify patterns of abnormalities associ-
ated with the clinical trajectory of illness development.
Taken in this context, the paper in this issue of EBioMedicine by Lee
and colleagues reports on ﬁndings of a cross-sectional study of neural
correlates and clinical outcomes up to 2 years later in 44 offspring of bi-
polar parents (Lin et al., 2015). High-risk offspring were divided into
subgroups comprising well (HR) or symptomatic/ultra-high-risk
(UHR) compared to healthy controls (C). Structural and functional neu-
roimaging and neurocognitive performance (i.e. processing speed and
visual spatial) and global functioning differences were found between
the groups and interpreted as evidence of differential indicators of BD
vulnerability and illness progression.
This study demonstrates the current and important trend of incor-
porating a multidimensional approach to assessing interactive illness
risk and progression processes in youth at conﬁrmed high-risk (Lin
et al., 2015). However, the interpretation of the speciﬁc ﬁndings should
be taken as preliminary given several limitations. Firstly, the study of
neural correlates was cross-sectional including only a small number of
high-risk offspring of a relatively wide age range (i.e. 8–28 years) and
with a limited clinical follow-up period (i.e. up to 2 years). The fact
that offspring with a prior diagnosis were excluded, suggests that
those included over age 20 may be resilient and different in measured
outcomes from younger subjects. In fact, other high-risk studies have
reported that the mean age of onset for major mood episodes is in
mid-adolescence and early risk syndromes, such as full-blown anxiety
or sleep disorders, manifest years earlier in mid-childhood (Duffy
et al., 2010; Mesman et al., 2013).
Furthermore, in this study – as in most others – the nature of the
subtype of BD in the parent is neglected (Lin et al., 2015). Yet, given
the substantial heterogeneity of the BD diagnosis – subsuming different
subtypes associated with characteristic differences in clinical, neurobio-
logical and neurocognitive ﬁndings – this is a major oversight that has
contributed to difﬁculties in replication of ﬁndings between studiesDOI of original article:http://dx.doi.org/10.1016/j.ebiom.2015.06.027.
URL: http://www.ﬂourishresearch.com.
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and contradictory ﬁndings reported in this study (i.e. increased small-
world properties in UHR). The smaller volumes in regions of interest
in HR offspring in this paper seems counter to ﬁndings reported by
Hajek et al. of increased right inferior frontal gyrus volumes in HR off-
spring and BD patients early in the illness course, while BD patients
with substantial illness burden showed decreased volumes which ap-
peared to bemitigated in those treatedwith lithium (Hajek et al., 2013).
Finally, this study divided high-risk offspring based on symptom sta-
tus following an approach used in conversion to psychosis studies
(Yung et al., 2004). The problem here is that the ultra-high-risk
concept has typically been used to refer to clinical at risk groups of
youth. Ideally, if the question is one of mapping biomarkers to clinical
illness progression, offspring should ideally be re-assessed in remission
or at their best level of functioning and their clinical course carefully
documented to place them on a clinical continuum of risk (clinical stag-
ing) andmap changes in outcomes to clinical progression taking into ac-
count burden of illness.
These points notwithstanding, this study contributes to an impor-
tant international effort to characterizemarkers of BD risk and develop-
ment at the clinical, biological and psychological levels and to explore
the relationship between these processes (Lin et al., 2015). It is an excit-
ing and timely effort, and we will undoubtedly continue to learn from
one another, comparing and contrasting similarities and differences in
ﬁndings taken in context of the methods applied, in order to advance
understanding. A single comprehensive clinical staging model based
on the evidence from longitudinal prospective offspring studies speciﬁc
to BD subtypes (rather than extrapolated fromﬁndings of studies of het-
erogeneous populations of psychotic youth), would be exceedingly
helpful to this effort (Duffy, 2014, 2015).While theremay be some sim-
ilarities between different illness trajectories and associated risk indica-
tors and processes across subtypes, it is important thatwe donot simply
generalize from one diseasemodel to the next or develop some one size
ﬁts all approach based on assumptive leaps rather than the evidence.
This would be akin to lumping other illnesses together (i.e. Parkinson's
disease andAlzheimer's dementia) based on some overlappingﬁndings,
despite important differences in etiology, clinical course and treatment
response.
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